Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-09-17
2011-11-01
Haddad, Maher (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S388240, C530S391100, C530S391300, C530S391700, C435S007100, C435S810000, C435S975000, C424S145100
Reexamination Certificate
active
08048417
ABSTRACT:
A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
REFERENCES:
patent: 4687732 (1987-08-01), Ward
patent: 5482698 (1996-01-01), Griffiths
patent: 5624659 (1997-04-01), Bigner et al.
patent: 5820858 (1998-10-01), Leturcq
patent: 5859205 (1999-01-01), Adair et al.
patent: 6335014 (2002-01-01), Kusakabe
patent: 03/075960 (2003-09-01), None
Vajdos et al. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J. Mol. Biol. Jul. 5, 2002, 320(2):415-28.
Eduardo Padlan, Anatomy of the antibody molecule. Mol Immunol. Feb. 1994;31(3):169-217.
Klimka et al.,Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. British Journal of Cancer (2000) 83:252-260.
Beiboer et al.,Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. J. Mol., Biol. (2000) 296:833-849).
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Casset et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem Biophys Res Commun. Jul. 18, 2003;307(1)198-205.
MacCallum et al. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. Oct. 11, 1996;262(5):732-45.
Balza et al. “Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin” FEBS Lett. 332:39-43 (1993).
Chinol et al, “Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity” Brit. J. Cancer, 78:189-197 (1998).
Chinol et al. “Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting” Nucl. Med. Commun. 18:176-182 (1997).
Cremonesi et al. “Three-step radioimmunotherapy with Yttrium-90 biotin: Dosimetry and pharmacokinetics in cancer patients” Eur. J. Nucl. Med. 26:110-120 (1999).
De Santis et al. “Novel antitenascin antibody with increased tumour localisation for pretargeted antibody-guided radio immunotherapy (Pagrit)” Brit. J. Cancer 88:996-1003 (2003).
Hart et al. “HPMA copolymer-modified avidin: Immune response” J. Biomaterials Sci. 11:1-12 (2000).
Paganelli et al. “Antibody-guided three-step therapy for high grade glioma with Yttrium-90 biotin” Eur. J. Nucl. Med. 26:348-357 (1999).
Prashanta et al. “Tenascin in human neoplasia: Immunohistochemical observations using seven different clones of monoclonal antibodies” Intl. J. Oncol. 8:741-755 (1996).
Reznik et al, “Streptavidins with intersubunit crosslinks have enhanced stability” Nature Biotechnol. 14:1007-1011 (1998).
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity” Proc. Natl. Acad. Sci. USA 79:1979-1983 (1982).
International Search Report for PCT/IT2003/00098 dated Jul. 16, 2003.
International Preliminary Examination Report for PCT/IT2003/00098 dated Feb. 3, 2004.
Anna Maria Anastasi
Rita De Santis
Haddad Maher
Lucas & Mercanti LLP
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Anti-human tenascin monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-human tenascin monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-human tenascin monoclonal antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4294077